Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Baker Heart and Diabetes Institute, Melbourne, Victoria 3000, Australia.
Mol Pharm. 2024 May 6;21(5):2473-2483. doi: 10.1021/acs.molpharmaceut.4c00026. Epub 2024 Apr 5.
In recent years, the drainage of fluids, immune cells, antigens, fluorescent tracers, and other solutes from the brain has been demonstrated to occur along lymphatic outflow pathways to the deep cervical lymph nodes in the neck. To the best of our knowledge, no studies have evaluated the lymphatic transport of therapeutics from the brain. The objective of this study was to determine the lymphatic transport of model therapeutics of different molecular weights and lipophilicity from the brain using cervical lymph cannulation and ligation models in rats. To do this, anesthetized Sprague-Dawley rats were cannulated at the carotid artery and cannulated, ligated, or left intact at the cervical lymph duct. Rats were administered C-ibuprofen (206.29 g/mol, logP 3.84), H-halofantrine HCl (536.89 g/mol, logP 8.06), or H-albumin (∼65,000 g/mol) via direct injection into the brain striatum at a rate of 0.5 μL/min over 16 min. Plasma or cervical lymph samples were collected for up to 6-8 h following dosing, and brain and lymph nodes were collected at 6 or 8 h. Samples were subsequently analyzed for radioactivity levels via scintillation counting. For C-ibuprofen, plasma concentrations over time (plasma AUC) were >2 fold higher in lymph-ligated rats than in lymph-intact rats, suggesting that ibuprofen is cleared from the brain primarily via nonlymphatic routes (e.g., across the blood-brain barrier) but that this clearance is influenced by changes in lymphatic flow. For H-halofantrine, >73% of the dose was retained at the brain dosing site in lymph-intact and lymph-ligated groups, and plasma AUC values were low in both groups (<0.3% dose.h/mL), consistent with the high retention in the brain. It was therefore not possible to determine whether halofantrine undergoes lymphatic transport from the brain within the duration of the study. For H-albumin, plasma AUC values were not significantly different between lymph-intact, lymph-ligated, and lymph-cannulated rats. However, >4% of the dose was recovered in cervical lymph over 8 h. Lymph/plasma concentration ratios of H-albumin were also very high (up to 53:1). Together, these results indicate that H-albumin is transported from the brain not only via lymphatic routes but also via the blood. Similar to other tissues, the lymphatics may thus play a significant role in the transport of macromolecules, including therapeutic proteins, from the brain but are unlikely to be a major transport pathway from the brain for small molecule drugs that are not lipophilic. Our rat cervical lymph cannulation model can be used to quantify the lymphatic drainage of different molecules and factors from the brain.
近年来,人们已经证明,液体、免疫细胞、抗原、荧光示踪剂和其他溶质从大脑中的排出是沿着淋巴流出途径到颈部的深部颈淋巴结进行的。据我们所知,尚无研究评估治疗药物从大脑中的淋巴转运。本研究的目的是使用大鼠的颈淋巴插管和结扎模型,确定不同分子量和亲脂性的模型治疗药物从大脑中的淋巴转运。为此,用麻醉的 Sprague-Dawley 大鼠通过颈动脉插管,并对颈淋巴导管进行插管、结扎或保持完整。通过直接将 C-布洛芬(206.29g/mol,logP3.84)、H-卤泛群盐酸盐(536.89g/mol,logP8.06)或 H-白蛋白(约 65000g/mol)注入大脑纹状体以 0.5μL/min 的速度输注 16min,以 0.5μL/min 的速度向大鼠脑内给药。在给药后长达 6-8 小时内采集血浆或颈淋巴样本,在 6 或 8 小时采集脑和淋巴结。随后通过闪烁计数分析样品中的放射性水平。对于 C-布洛芬,与淋巴未结扎组相比,淋巴结扎组的血浆浓度时间曲线下面积(AUC)高出 2 倍以上,这表明布洛芬主要通过非淋巴途径(例如穿过血脑屏障)从大脑中清除,但淋巴流量的变化会影响这种清除。对于 H-卤泛群,在淋巴未结扎和结扎组中,>73%的剂量保留在脑内给药部位,两组的血浆 AUC 值均较低(<0.3%剂量.h/mL),这与在大脑中的高保留相一致。因此,在研究期间无法确定卤泛群是否从大脑中进行淋巴转运。对于 H-白蛋白,淋巴未结扎、结扎和淋巴插管组之间的血浆 AUC 值无显著差异。然而,在 8 小时内有>4%的剂量回收于颈淋巴中。H-白蛋白的淋巴/血浆浓度比也非常高(高达 53:1)。总之,这些结果表明,H-白蛋白不仅通过淋巴途径,而且还通过血液从大脑中转运。类似于其他组织,淋巴管可能在大分子(包括治疗性蛋白质)从大脑中的转运中发挥重要作用,但对于亲脂性差的小分子药物而言,它们不太可能成为大脑的主要转运途径。我们的大鼠颈淋巴插管模型可用于定量从大脑中排出不同分子和因素的淋巴引流。